Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

33 results about "Lipid A synthesis" patented technology

Paclitaxel lipid composite

The invention discloses a paclitaxel lipid complex. The paclitaxel lipid complex consists of paclitaxel and lipid material. The weight proportion of the paclitaxel and the lipid material is 1 to 1 - 19, the preferential proportion is 1 to 2 - 10, and the more preferential proportion is 1 to 3 - 6. The lipid material is selected from natural lipid and synthetic lipid or the mixture thereof. The paclitaxel lipid complex can also contain antioxidation stabilizer. The invention also discloses a preparation method of the paclitaxel lipid complex and the application in the preparation of injection submicron emulsion and dry emulsion. The paclitaxel lipid complex has high solubility in oil, and the prepared submicron emulsion has the advantages of high drug loading quantity, high stability, high safety and low irritability.
Owner:BEIJING WEHAND BIO PHARMA CO LTD

Mutants of gram negative mucosal bacteria and application thereof in vaccines

It is possible to inactivate the early stage of lipid A synthesis of mucosal gram negative bacteria without compromising cell viability. In particular the lpxA gene in N. meningitidis was mutated and resulting lpxA knockout mutants were found to be completely lipopolysaccharide (LPS)-deficient. The major outer membrane proteins (OMPs) were detected in normal amounts. The finding provides important implications for understanding of structure and biogenesis of the outer membrane. On a practical level, the availability of LPS-deficient mutants of pathogenic mucosal bacteria such as N. meningitidis opens up new avenues to vaccine development. It enables easy isolation of endotoxin-free purified proteins, outer membranes or even whole-cell preparations for use in immunisation.
Owner:INTRAVACC BV +1

Health products with hypolipemic function, preparation method and usage thereof

ActiveCN101524422AClear blood lipid depositsInhibit endogenous cholesterol synthesis and low-density lipoprotein productionOrganic active ingredientsMetabolism disorderToxicityAdemetionine
The invention relates to health products with hypolipemic function and also relates to a preparation method for the health products and the usage thereof. The health products comprise active constituents of hongqu powder, hawthorn extract, ginkgo biloba leaf extract, obtuseleaf senna seed extract and radix salviae miltiorrhizae extract. The active constituents have very obvious synergistic effect, thus playing a positive role in hypolipemic in many aspects such as reducing endogenous lipid synthesis, promoting the transfer and excretion of lipid, regulating lipid metabolism and the like, having obvious hypolipemic effect; safety toxicity test proves that the active constituents are safe, innoxious and harmless.
Owner:WUXI JIANTE PHARM CO LTD +1

Heterocyclic modulators of lipid synthesis

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and / or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatits C infection, cancer and metabolic disorders.
Owner:GANNEX PHARM CO LTD

Application of soluble dietary fibers in kelp in preparation of lipid-lowering and weight-losing medicines and functional foods

The invention discloses an application of soluble dietary fibers in kelp in preparation of lipid-lowering and weight-losing medicines and functional foods. The soluble dietary fibers are extracted from the waste kelp residues, after feeding for 3 weeks, the weight of obese mice is remarkably reduced compared with that of a negative control group; after 6 weeks of experiment period, the lipid-lowering effect is obvious; the epididymis fat and the liver of a mouse are subjected to histopathological section, the soluble dietary fibers in the section dyed by HE can obviously reduce the size of thefat, and the fat lesion of the liver of the mouse is relieved. By detecting mRNA expression of related factors related to lipid metabolism in fat and liver and mRNA expression of common inflammatoryfactors in obesity, the soluble dietary fibers can down-regulate expression of lipid synthesis genes and pro-inflammatory factors and up-regulate expression of lipid metabolism genes. The soluble dietary fiber disclosed by the invention is high in safety and low in price, and has a remarkable effect in the aspects of reducing fat and losing weight of OB obese mice.
Owner:THE FIRST INST OF OCEANOGRAPHY SOA

Heterocyclic modulators of lipid synthesis for use against cancer and viral infections

The invention discloses heterocyclic modulators of lipid synthesis for use against cancer and viral infections. According to the invention, also provided are heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and methods of treating conditions characterized by disregulation of a fatly acid synthase pathway by the administration of such compounds.
Owner:GANNEX PHARM CO LTD

Heterocyclic modulators of lipid synthesis

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and / or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatitis C infection, cancer and metabolic disorders, such as non-alcoholic steatohepatitis (NASH).
Owner:3 V BIOSCI INC

Applications of 18beta-glycyrrhetinic acid in preparation drugs for diseases related to abnormal lipid metabolism

The invention discloses applications of 18beta-glycyrrhetinic acid taken as a conditioning agent for reduce lipid synthesis and / or the conditioning agent for reducing very low density lipoprotein formation and secretion in drugs. A drug containing the 18beta-glycyrrhetinic acid with effective doses is disclosed; the 18beta-glycyrrhetinic acid can be taken as a conditioning agent of HNF4alpha and can lower the expression of APOB, MTP and PLA2G12B; and a method for inhibiting the expression of FASN, SCD-1 and ACAC[alpha] is also disclosed. The 18beta-glycyrrhetinic acid can inhibit the expression of lipid metabolism related genes, so that lipid synthesis and the formation and secretion of very low density lipoprotein can be inhibited, lipid content in the liver can be lowered, the fatty degree of the liver can be reduced, liver functions can be obviously improved, blood fat can be reduced, and the effects of preventing and / or treating diseases related to abnormal lipid metabolism can befinally achieved. In addition, as the 18beta-glycyrrhetinic acid is a natural substance, the 18beta-glycyrrhetinic acid is good in curative effect and small in toxic and side effect.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Application of rosustat in medicine for inhibiting acute alcoholic fatty liver

The invention provides an application of rosustat in a medicine for inhibiting acute alcoholic fatty liver. Roxasstat can significantly inhibit liver injury and lipid accumulation caused by acute alcohol. According to the mechanism, rosustat plays a role in inhibiting mouse liver lipid accumulation mainly by regulating and controlling the expression of lipid synthesis key genes. The medicine is expected to become an effective medicine for clinically treating the alcoholic fatty liver.
Owner:ZHEJIANG JIANFENG PHARM CO LTD

Heterocyclic modulators of lipid synthesis

Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and / or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatits C infection, cancer and metabolic disorders.
Owner:3 V BIOSCI INC

Application of ZNRF3/RNF43 in preparation of medicine for regulating energy metabolism

The invention relates to application of ZNRF3 / RNF43 in preparation of a medicine for regulating energy metabolism. It proves that the ZNRF3 / RNF43 double knockout can reduce the blood sugar content andserum insulin level, increase the sensitivity of the body to glucose and down-regulate the expression of glucose allogeneic related genes; meanwhile, liver lipid deposition is reduced, lipid synthesis and expression of inflammation-related genes are reduced, it is shown that the ZNRF3 / RNF43 double knockout can improve liver insulin resistance possibly through the ways of influencing glycoxenesis,lipid synthesis and the like, and then a theoretical basis is provided for preparing energy metabolism regulating medicine.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1

A kind of β-isopropylmalate dehydrogenase and its application in lipid synthesis

The invention discloses beta-isopropylmalate dehydrogenase and application of the beta-isopropylmalate dehydrogenase in lipid synthesis, and belongs to the technical fields of gene engineering and microbial engineering. An amino acid sequence of the beta-isopropylmalate dehydrogenase is shown in SEQ ID No. 1, and the beta-isopropylmalate dehydrogenase has a function of promoting microorganism to produce fatty acids. Recombinant mortierella alpina containing the beta-isopropylmalate dehydrogenase is subjected to shake cultivation for 7 d, so that the fatty acid content in the mortierella alpinacontaining the beta-isopropylmalate dehydrogenase can reach 46.4% of dry cell weight, and is 20.2% higher than that of mortierella alpina without the beta-isopropylmalate dehydrogenase. According tothe beta-isopropylmalate dehydrogenase, through gene engineering, the fatty acid production ability of the mortierella alpine and other oil producing microorganisms is further improved, and solid theoretical support for improving the fatty acid biosynthesis ability is provided.
Owner:JIANGNAN UNIV

Productivity and Bioproduct Formation in Phototropin Knock/Out Mutants in Microalgae

Phototropin is a blue light receptor, which mediates a variety of blue-light elicited physiological processes in plants and algae. In higher plants these processes include phototropism, chloroplast movement and stomatal opening. In the green alga Chlamydomonas reinhardtii, phototropin plays a vital role in progression of the sexual life cycle and in the control of the eye spot size and light sensitivity Phototropin is also involved in blue-light mediated changes in the synthesis of chlorophylls, carotenoids, chlorophyll binding proteins. We compared the transcriptome of phototropin knock out (PHOT KO) mutant and wild-type parent to analyze differences in gene expression in high light grown cultures (500 μmol photons m−2s−1). Our results indicate the up-regulation of genes involved in photosynthetic electron transport chain, carbon fixation pathway, starch, lipid, and cell cycle control genes. With respect to photosynthetic electron transport genes, genes encoding proteins of the cytochrome b6f and ATP synthase complex were up regulated potentially facilitating proton-coupled electron transfer. In addition genes involved in limiting steps in the Calvin cycle Ribulose-1,5-bisphosphate carboxylase / oxygenase (RuBisCO), Sidoheptulose 1,7 bisphosphatase (SBPase), Glyceraldehyde-3-phosphate dehydrogenase (3PGDH) and that mediate cell-cycle control (CDK) were also up regulated along with starch synthase and fatty acid biosynthesis genes involved in starch and lipid synthesis. In addition, transmission electron micrographs show increased accumulation of starch granules in PHOT mutant compared to wild type, which is consistent with the higher expression of starch synthase genes. Collectively, the altered patterns of gene expression in the PHOT mutants were associated with a two-fold increase in growth and biomass accumulation compared to wild type when grown in environmental photobioreactors (Phenometrics) that simulate a pond environment. In conclusion, our studies suggest that phototropin may be a master gene regulator that suppresses rapid cell growth and promotes gametogenesis and sexual recombination in wild type strains.
Owner:TRIAD NAT SECURITY LLC +1

Application of transcription factor KLF16 protein in preparing drugs for preventing and treating diseases related to abnormal lipid and glucose metabolism

The invention provides an application of a transcription factor KLF16 protein in the preparation of drugs for preventing and treating diseases related to abnormal lipid and glucose metabolism. The transcription factor KLF16 protein provided by the invention significantly reduces the blood sugar and blood lipid level in disease model animals by mediating and regulating the expression of gluconeogenesis-related genes, and has effects of inhibiting gluconeogenesis and inhibiting lipid synthesis and deposition, and thereby inhibits the progress of hyperglycemia and hyperlipidemia. Therefore, the transcription factor KLF16 protein has the potential of preventing and treating diseases caused by hyperglycemia and hyperlipidemia such as diabetes, diabetic complications, obesity, hyperinsulinemia,hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and arteriosclerosis, and a new target for the prevention and treatment of the above-mentioned diseases, especially type II diabetes and obesity is provided. The KLF16 protein has no toxic side effects, has good safety, can adapt to the industrial application of new drugs, and has good clinical application prospect.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE

Compositions and methods for treating obesity and hyperphagia

The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and / or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.
Owner:MHS CARE INNOVATION LLC

Application of theaflavin TF3 to preparation of PK (plasma kallikrein) inhibitor and medicines for NAFLD (non-alcoholic fatty liver disease) treatment

The invention belongs to the technical field of pharmaceutical preparations and particularly relates to application of theaflavin TF3 to preparation of a PK (plasma kallikrein) inhibitor and medicinesfor NAFLD (non-alcoholic fatty liver disease) treatment. By a direct inhibition effect of tea monomer theaflavin TF3 (theaflavin-3, 3'-gallate) on PK targets in NAFLD liver cells, TF3 is capable of remarkably inhibiting PK enzymatic activity and further remarkably activating AMPK signal routing after PK inhibition to reduce lipid synthesis protein expression and activate or stimulate lipidolysisprotein expression and is also capable of reducing accumulation of intracellular lipids through PK activity inhibition. Therefore, the theaflavin TF3 can be used as a newly discovered PK inhibitor with a certain regulation function in fat metabolism pathway, plays a key role in NAFLD improvement, has an effect of NAFLD treatment or alleviation and can be applied to medicines for NAFLD prevention,treatment or alleviation.
Owner:TEA RES INST GUANGDONG ACAD OF AGRI SCI

Application of Nomilin in Preparation of Drugs for Improving Liver Damage Caused by Cholestasis and Metabolic Diseases

The invention relates to the application of nomilin in the preparation of medicines for improving liver damage caused by cholestasis and metabolic diseases, and belongs to the technical field of medicine preparation. The present invention provides the application of nomilin in the preparation of medicines for improving liver damage caused by cholestasis and metabolic diseases. Nomilin can significantly improve liver damage by improving bile acid metabolism, anti-inflammatory, anti-oxidative stress, and reducing lipid synthesis.
Owner:SHANGHAI UNIV OF T C M

Compositions comprising pyridine carboxylate herbicides and fatty acid and lipid synthesis inhibitor herbicides

Disclosed herein are compositions comprising (a) a pyridine carboxylate herbicide or an agriculturally acceptable N-oxide, salt, or ester thereof and (b) a fatty acid and lipid synthesis inhibitor (FA / LSI) herbicide, an agriculturally acceptable salt or ester thereof, or mixtures thereof. Also disclosed herein are methods of controlling undesirable vegetation, comprising applying to vegetation or an area adjacent the vegetation or applying in soil or water to control the emergence or growth of vegetation (a) a pyridine carboxylate herbicide or an agriculturally acceptable N-oxide, salt, or ester thereof and (b) a fatty acid and lipid synthesis inhibitor (FA / LSI) herbicide, an agriculturally acceptable salt or ester thereof, or mixtures thereof.
Owner:CORTEVA AGRISCIENCE LLC

Citric acid transport protein and application thereof in lipid synthesis

The invention discloses a citric acid transport protein and application thereof in lipid synthesis, belonging to the technical field of genetic engineering and microbial engineering. The citric acid-ketoglutarate transport protein with an amino acid sequence shown as SEQ ID No. 1 has the function of promoting microorganisms to produce fatty acid; after recombinant mortierella alpine containing the citric acid-ketoglutarate transport protein is subjected to shaking culture for 7 days, the fatty acid content of mortierella alpine containing the citric acid-ketoglutarate transport protein can reach 36.1% of the dry weight of cells, and is increased by 30.4% compared with the fatty acid content of mortierella alpine not containing the citric acid-ketoglutarate transport protein. Through a genetic engineering means, the lipid synthesis accumulation capacity of oil-producing microorganisms such as mortierella alpine is improved on a gene level, and meanwhile, the normal growth of the oil-producing microorganisms can be ensured, so a technical support is provided for more efficient microbial oil industrial production.
Owner:JIANGNAN UNIV

Productivity and bioproduct formation in phototropin knock/out mutants in microalgae

Phototropin is a blue light receptor, which mediates a variety of blue-light elicited physiological processes in plants and algae. In higher plants these processes include phototropism, chloroplast movement and stomatal opening. In the green alga Chlamydomonas reinhardtii, phototropin plays a vital role in progression of the sexual life cycle and in the control of the eye spot size and light sensitivity Phototropin is also involved in blue-light mediated changes in the synthesis of chlorophylls, carotenoids, chlorophyll binding proteins. We compared the transcriptome of phototropin knock out (PHOT KO) mutant and wild-type parent to analyze differences in gene expression in high light grown cultures (500 μmol photons m−2 s−1). Our results indicate the up-regulation of genes involved in photosynthetic electron transport chain, carbon fixation pathway, starch, lipid, and cell cycle control genes. With respect to photosynthetic electron transport genes, genes encoding proteins of the cytochrome b6f and ATP synthase complex were up regulated potentially facilitating proton-coupled electron transfer. In addition genes involved in limiting steps in the Calvin cycle Ribulose-1,5-bisphosphate carboxylase / oxygenase (RuBisCO), Sidoheptulose 1,7 bisphosphatase (SBPase), Glyceraldehyde-3-phosphate dehydrogenase (3PGDH) and that mediate cell-cycle control (CDK) were also up regulated along with starch synthase and fatty acid biosynthesis genes involved in starch and lipid synthesis. In addition, transmission electron micrographs show increased accumulation of starch granules in PHOT mutant compared to wild type, which is consistent with the higher expression of starch synthase genes. Collectively, the altered patterns of gene expression in the PHOT mutants were associated with a two-fold increase in growth and biomass accumulation compared to wild type when grown in environmental photobioreactors (Phenometrics) that simulate a pond environment. In conclusion, our studies suggest that phototropin may be a master gene regulator that suppresses rapid cell growth and promotes gametogenesis and sexual recombination in wild type strains.
Owner:NMC INC +1

Cell culture medium, cell culture kit and cell culture method

The invention relates to a cell culture medium. The cell culture medium contains a basal culture medium, a serum substitute, linoleic acid, testosterone, vitamin A, L-ascorbic acid, polylysine, putrescine, and 2-mercaptoethanol. The cell culture medium of the invention can efficiently culture sebaceous gland cells in vitro, so that a cell proliferation rate, a survival rate after resuscitation, and an expression amount of lipid synthesis related proteins of different generations of the sebaceous gland cells are significantly increased, and thereby the assistance for extensively researching sebaceous gland physiological and endocrine functions, exploring pathogenesis of sebaceous gland related diseases, and developing drugs is provided.
Owner:GUANGDONG BOXI BIO TECH CO LTD

Method and preparation for regulating lipid secretion of retinal pigment epithelial cells and application thereof

The invention provides a method and a preparation for regulating lipid secretion of retinal pigment epithelial cells, and application thereof, and the method is characterized in that activation of an SREBP-1 site is inhibited by inhibiting a PDGF-D signal channel, so that the lipid secretion amount of the retinal pigment epithelial cells is reduced. The PDGF-D has an adjusting effect on an SREBP-1 signal channel, and activation of SREBP1 can be inhibited by inhibiting expression of the PDGF-D, so that expression of a lipid synthase gene is reduced, lipid synthesis in RPE is reduced, and formation of lipid deposition under the retina is reduced.
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV

Culture method for promoting microalgae fucoxanthin accumulation and lipid synthesis

The invention discloses a culture method for promoting accumulation of microalgae fucoxanthin and lipid synthesis, which comprises the following steps: inoculating microalgae into a culture medium for culture, and adding 150-350mg / L of L-ascorbic acid into the culture medium. According to the culture method disclosed by the invention, the fucoxanthin content of the phaeodactylum tricornutum can be increased, and meanwhile, the lipid content of the phaeodactylum tricornutum, especially the content of eicosapentaenoic acid (EPA), is increased.
Owner:FUJIAN AGRI & FORESTRY UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products